Europe — EMA

Paclitaxel Accord

Paclitaxel, the active ingredient in Paclitaxel Accord, is a taxane presented as a strength/form for intravenous use. It is employed in the treatment of various cancers in adult patients.

Paclitaxel

Request sourcing

Pack/s

What is Paclitaxel?

Paclitaxel, the active ingredient in Paclitaxel Accord, is a taxane presented as a strength/form for intravenous use. It is employed in the treatment of various cancers in adult patients. GNH USA supplies Paclitaxel Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Paclitaxel Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Paclitaxel used for?

Paclitaxel Accord is a chemotherapeutic agent that acts on solid tumours and related pathways.

- Breast cancer: Improves the overall response rate and survival in patients with advanced disease. - Ovarian cancer: Enhances the efficacy of first‑line platinum based regimens and prolong the progression‑free interval. - Non‑small cell lung cancer: Provides benefits in tumour shrink and disease control for patients with advanced NSCLC. - Kaposi sarcoma associated with . - . -

What are the side effects of Paclitaxel?

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →